Antibodies targeting glioblastoma stem-like cells and methods of use thereof
US-2024018263-A1 · Jan 18, 2024 · US
Molecular imaging of cancer cells in vivo
US11077212B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11077212-B2 |
| Application number | US-201113813605-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2011 |
| Priority date | Aug 24, 2010 |
| Publication date | Aug 3, 2021 |
| Grant date | Aug 3, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
First claim
Opening claim text (preview).
We claim: 1. A non-invasive method for in vivo detection of metastasized breast cancer cells in a subject, the method comprising the steps of: (a) administering to the subject a first targeted imaging probe and a second targeted imaging probe, wherein the targeted imaging probes each comprise an antibody linked to a NIR fluorophore, wherein the antibody of the first imaging probe specifically binds carbonic anhydrase 9 (CAIX), wherein the antibody of the second imaging probe specifically binds carbonic anhydrase 12 (CAXII); and (b) imaging the subject with a molecular imaging device to detect the targeted imaging probes in the subject, wherein detection of the targeted imaging probes in an organ or a tissue of the subject is an indication of metastasized breast cancer cells in the organ or the tissue. 2. The method of claim 1 , wherein the antibody that specifically binds CAIX is monoclonal antibody clone 303123 and the antibody that specifically binds CAXII is monoclonal antibody clone 315602. 3. A non-invasive method for intraoperative detection of metastasized breast cancer cells in a subject, the method comprising the steps of: (a) administering to the subject a first targeted imaging probe and a second targeted imaging probe, wherein the targeted imaging probes each comprise an antibody linked to a near-infrared (NIR) fluorophore, and wherein the antibody of the first targeted imaging probe specifically binds carbonic anhydrase 9 (CAIX), wherein the antibody of the second targeted imaging probe specifically binds carbonic anhydrase 12 (CAXII); and (b) imaging the subject with a molecular imaging device to detect the targeted imaging probes in the subject, wherein detection of the targeted imaging probes in an organ or a tissue of the subject is an indication of metastasized breast cancer cells in the organ or the tissue. 4. The method of claim 3 , wherein the antibody that specifically binds CAIX is monoclonal antibody clone 303123. 5. The method of claim 3 , wherein the antibody that specifically binds CAXII is monoclonal antibody clone 315602. 6. The method of claim 3 , wherein the antibody that specifically binds CAIX is monoclonal antibody clone 303123, and wherein the antibody that specifically binds CAXII is monoclonal antibody clone 315602. 7. The method of claim 3 further comprising removing the metastasized breast cancer cells identified via the imaging from the organ or the tissue of the subject. 8. The method of claim 3 further comprising treating the subject for cancer if the imaging indicates the presence of metastasized breast cancer cells. 9. The method of claim 8 further comprising repeating the steps of claim 1 following treatment. 10. The method of claim 3 , wherein the metastasized breast cancer cells are breast cancer cells metastasized to one or more lymph nodes. 11. The method of claim 10 , wherein the one or more lymph nodes are axillary lymph node and/or sentinel lymph nodes.
Assignees
Inventors
Classifications
- A61K49/0058Primary
Antibodies · CPC title
General or multifunctional contrast agents, e.g. chelated agents · CPC title
against animal or human tumor cells or tumor cell determinants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11077212B2 cover?
- Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
- Who is the assignee on this patent?
- Morse David L, Gillies Robert J, Carter William Bradford, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K49/0058. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).